Eton Pharmaceuticals, Inc. (ETON) Stock Forecast
ETON analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $71.50 average of analyst targets
- Upside to target
- +42.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.34
- 52-week range
- $14.35 – $64.43
ETON analyst ratings
4 analystsNumber of analysts at each rating.
ETON price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ETON earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.37 | $0.32 | $0.42 | $0.04 | +825.0% | 2 |
| Current fiscal year (2026) | $1.40 | $1.28 | $1.52 | $0.32 | +337.5% | 2 |
| Next fiscal year (2027) | $2.55 | $2.11 | $2.99 | $1.40 | +82.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ETON revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $42.2M | $40.5M | $43.1M | +87.9% | 3 |
| Current fiscal year (2026) | $149.7M | $147.6M | $152.3M | +87.3% | 4 |
| Next fiscal year (2027) | $220.4M | $203.1M | $236.6M | +47.2% | 4 |
ETON EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ETON revenue: reported and forecast
ETON EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.31 | $0.37 | $0.37 | $0.37 | $0.37 | +19.4% | 1 up · 0 down |
| Current fiscal year (2026) | $1.04 | $1.40 | $1.40 | $1.40 | $1.40 | +34.0% | 1 up · 0 down |
| Next fiscal year (2027) | $2.14 | $2.58 | $2.58 | $2.58 | $2.55 | +19.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ETON earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ETON beat in 6 of 12.
What analysts expect from ETON
4 analysts cover Eton Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $71.50, 42.1% above the latest close of $50.31. Analysts expect earnings of $1.40 per share for 2026, +337.5% from a year earlier. For 2027 the average estimate is $2.55 per share on revenue of $220.4 million. Eton Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: ETON income statement, ETON key metrics, ETON chart. See the ETON stock overview for the latest quote and news.
ETON forecast FAQ
What is Eton Pharmaceuticals's price target?
The average analyst price target for Eton Pharmaceuticals is $71.50, 42.1% above the latest close of $50.31.
Is Eton Pharmaceuticals a buy, hold or sell?
Of 4 analysts covering Eton Pharmaceuticals, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eton Pharmaceuticals's EPS forecast?
Analysts forecast $1.40 per share for 2026 (range $1.28 to $1.52); for 2027 the estimate is $2.55.
What is Eton Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $149.7 million, growth of 87.3%; for 2027 it is $220.4 million.
When does Eton Pharmaceuticals report earnings?
Eton Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $0.34.
Does Eton Pharmaceuticals usually beat earnings estimates?
Eton Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.